Format

Send to

Choose Destination
JAMA Surg. 2019 Jun 1;154(6):e190484. doi: 10.1001/jamasurg.2019.0484. Epub 2019 Jun 19.

Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.

Author information

1
Computational Biology Group, Department of Biosystems Science and Engineering, ETH Zurich, Zurich, Switzerland.
2
Swiss Institute of Bioinformatics, Basel, Switzerland.
3
Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
4
Institute for Pathology, Cantonal Hospital of Winterthur, Winterthur, Switzerland.
5
Department of General and Visceral Surgery, Ulm University Hospital, Ulm, Germany.
6
Senckenberg Institute for Pathology, Goethe University Hospital Frankfurt, Frankfurt, Germany.
7
Institute for Regenerative Medicine, University of Zurich, Zurich, Switzerland.
8
Department of General, Visceral and Thoracic Surgery, Klinikum Dessau, Dessau, Germany.
9
Department of Visceral and Transplantation Surgery, University Hospital Zurich, Zurich, Switzerland.
10
Department of Visceral and Thoracic Surgery, Cantonal Hospital of Winterthur, Winterthur, Switzerland.
11
Ludwig Institute for Cancer Research, University of Oxford, Oxford, United Kingdom.

Abstract

Importance:

Surgery currently offers the only chance for a cure in pancreatic ductal adenocarcinoma (PDAC), but it carries a significant morbidity and mortality risk and results in varying oncologic outcomes. At present, to our knowledge, there are no tests available before surgical resection to identify tumors with an aggressive biological phenotype that could guide personalized treatment strategies.

Objective:

Identification of noninvasive genetic biomarkers that could direct therapy in patients whose cases are amenable to pancreatic cancer resection.

Design, Setting, and Participants:

This multicenter study combined a prospective European cohort of patients with PDAC who underwent pancreatic resection (from University Hospital of Zurich, Zurich, Switzerland; Cantonal Hospital of Winterthur, Winterthur, Switzerland; and University Clinic of Ulm, Ulm, Germany) with data from the Cancer Genome Atlas database in the United States, which includes prospectively registered patients with PDAC. A genome-wide screening for functional single-nucleotide polymorphisms (SNPs) that affect PDAC survival was conducted using the European cohort for identification and the Cancer Genome Atlas cohort for validation. We used Cox proportional hazards models to screen for high-frequency polymorphic variants that are associated with allelic differences in tumor-associated survival and either result in an altered protein structure and function or reside in known regulatory noncoding genomic regions. The false-discovery rate method was applied for multiple hypothesis-testing corrections. Data analysis occurred from November 2017 to May 2018.

Exposures:

Pancreatic resection.

Main Outcomes and Measures:

Tumor-associated survival.

Results:

A total of 195 patients in the European cohort were included, as well as 136 patients in the Cancer Genome Atlas cohort (overall median [range] age, 66 [19-87] years; 156 [47.1%] were women, and 175 [52.9%] were men). Two SNPs in noncoding, functional regions of genes that regulate cancer progression, invasion, and metastasis were identified (CHI3L2 SNP rs684559 and CD44 SNP rs353630). These were associated with survival after PDAC resection; patients who carry the risk alleles at 1 of both SNP loci had a 2.63-fold increased risk for tumor-associated death compared with those with protective genotypes (hazard ratio for survival, 0.38 [95% CI, 0.27-0.53]; P = 1.0 × 10-8).

Conclusions and Relevance:

The identified polymorphisms may serve as a noninvasive biomarker signature of prospective survival after pancreatic resection that is readily available at the time of PDAC diagnosis. This signature can be used to identify a subset of high-risk patients with PDAC with very low survival probability who might be eligible for inclusion in clinical trials of new therapeutic strategies, including neoadjuvant chemotherapy protocols. In addition, the biological knowledge about these SNPs could help guide the development of individualized genomic strategies for PDAC therapies.

PMID:
30942874
PMCID:
PMC6583393
DOI:
10.1001/jamasurg.2019.0484

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center